• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Consistency of the efficacy of cetirizine and ebastine on skin reactivity.

作者信息

Frossard N, Melac M, Benabdesselam O, Pauli G

机构信息

INSERM U 425, Service de Pneumologie, Hôpitaux Universitaires, Strasbourg, France.

出版信息

Ann Allergy Asthma Immunol. 1998 Jan;80(1):61-5. doi: 10.1016/S1081-1206(10)62941-9.

DOI:10.1016/S1081-1206(10)62941-9
PMID:9475569
Abstract

BACKGROUND

At therapeutic dosage, cetirizine and ebastine induce significant inhibition of skin reactivity to histamine. The consistency of their efficacy, that is, efficacy with the least interindividual variability among subjects, has not been carefully assessed, however.

OBJECTIVE

To compare the consistency and efficacy of these antihistamines on skin reactivity.

METHODS

Twenty-four healthy volunteers participated in a randomized double-blind crossover study. The areas of wheals and flares induced by increasing (0, 5, 10, 50, 100, 200, and 300 mg/mL) histamine concentrations, administered by prick tests, were measured before and four hours after intake of 10 mg of each antihistamine, allowing concentration-response curves to be established. The threshold histamine concentrations inducing wheal areas of 3 mm2 (positivity) were calculated by interpolation. The coefficient of variation (SD/mean %) was used to evaluate the consistency of the response.

RESULTS

Pretreatment concentration-response curves were similar, and threshold concentrations identical (0.29 mg/mL and 0.34 mg/mL for cetirizine and ebastine, respectively). For both, curves were lower after treatment than before. After cetirizine, the threshold concentration was significantly higher (217 mg/mL) than after ebastine (0.82 mg/mL) (P < .001), and total inhibition of the wheal reaction was observed in 21 of 24 patients at the lowest histamine concentration and in 17 of 24 at the highest. Ebastine never totally inhibited reaction, even to 5 mg/mL of histamine. Over the entire concentration-response curve, the coefficient of variation for the wheal reaction was 6.3% for cetirizine and 72.6% for ebastine, and, for flares, 11.0% and 83.7%, respectively. Hence, variability was much lower after cetirizine.

CONCLUSION

Our study shows clearly that the efficacy of a single therapeutic dosage of cetirizine is consistently good for suppression of cutaneous reactivity to histamine in healthy volunteers. The need for ebastine to metabolize into the active carebastine might explain its lesser consistency.

摘要

相似文献

1
Consistency of the efficacy of cetirizine and ebastine on skin reactivity.
Ann Allergy Asthma Immunol. 1998 Jan;80(1):61-5. doi: 10.1016/S1081-1206(10)62941-9.
2
Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity.西替利嗪(10毫克)与依巴斯汀(20毫克)在4小时时对皮肤反应性的一致性和疗效。
Eur J Clin Pharmacol. 1999 Oct;55(8):589-92. doi: 10.1007/s002280050677.
3
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.左西替利嗪与依巴斯汀、非索非那定、氯雷他定、咪唑斯汀及安慰剂的双盲、随机、单剂量、交叉对照比较:健康男性受试者24小时内组胺诱导的风团及潮红反应抑制情况
Ann Allergy Asthma Immunol. 2002 Feb;88(2):190-7. doi: 10.1016/S1081-1206(10)61995-3.
4
Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers.在健康志愿者皮肤中进行稳态治疗24小时时,依巴斯汀(10毫克和20毫克)和西替利嗪的活性。
Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):409-13. doi: 10.1111/j.1472-8206.2000.tb00423.x.
5
Suppression of the skin reaction to histamine by ebastine.
Ann Allergy Asthma Immunol. 1995 May;74(5):442-7.
6
Twenty-four hours of activity of cetirizine and fexofenadine in the skin.西替利嗪和非索非那定在皮肤中的24小时活性。
Ann Allergy Asthma Immunol. 2001 Apr;86(4):387-92. doi: 10.1016/S1081-1206(10)62483-0.
7
Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges.依巴斯汀、西替利嗪和氯雷他定在组胺皮肤激发试验中的疗效。
Ann Allergy Asthma Immunol. 2002 Sep;89(3):259-64. doi: 10.1016/S1081-1206(10)61952-7.
8
Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis.西替利嗪与依巴斯汀治疗常年性变应性鼻炎的疗效和安全性比较。
Ann Allergy Asthma Immunol. 1998 May;80(5):399-403. doi: 10.1016/S1081-1206(10)62991-2.
9
Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults.成人季节性过敏性鼻炎中依巴斯汀与西替利嗪的比较。
Ann Allergy Asthma Immunol. 1996 Jun;76(6):507-12. doi: 10.1016/S1081-1206(10)63269-3.
10
Inhibition of the histamine wheal by ebastine compared with cetirizine, fexofenadine and loratadine at steady state.与西替利嗪、非索非那定和氯雷他定稳态时相比,依巴斯汀对组胺风团的抑制作用。
Drugs Exp Clin Res. 2002;28(6):243-7.

引用本文的文献

1
Second-generation antihistamines: actions and efficacy in the management of allergic disorders.第二代抗组胺药:在过敏性疾病管理中的作用与疗效
Drugs. 2005;65(3):341-84. doi: 10.2165/00003495-200565030-00004.
2
Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.左西替利嗪和地氯雷他定在皮肤中的24小时活性及活性一致性
Br J Clin Pharmacol. 2003 Oct;56(4):388-94. doi: 10.1046/j.1365-2125.2003.01897.x.
3
Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h.
西替利嗪和咪唑斯汀在24小时对组胺诱导的皮肤风团和潮红反应的比较活性。
Br J Clin Pharmacol. 2002 Mar;53(3):250-4. doi: 10.1046/j.0306-5251.2001.01551.x.
4
New insights into the second generation antihistamines.第二代抗组胺药的新见解。
Drugs. 2001;61(2):207-36. doi: 10.2165/00003495-200161020-00006.
5
Ebastine: an update of its use in allergic disorders.依巴斯汀:其在过敏性疾病中应用的最新进展
Drugs. 2000 Apr;59(4):981-1006. doi: 10.2165/00003495-200059040-00018.
6
Second-generation antihistamines: a comparative review.第二代抗组胺药:比较性综述
Drugs. 1999 Jan;57(1):31-47. doi: 10.2165/00003495-199957010-00004.